{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:27:28Z","timestamp":1774020448399,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T00:00:00Z","timestamp":1423612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>We report on a retrospective analysis of 147 patients with early and locoregionally advanced squamous cell head and neck cancer (SCCHN) treated with helical tomotherapy (HT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Included were patients with SCCHN of the oral cavity (OC), oropharynx (OP), hypopharynx (HP), or larynx (L) consecutively treated in one radiotherapy center in 2008 and 2009. The prescribed HT dose was 60\u201366 Gy in the postoperative setting (group A) and 66\u201370 Gy when given as primary treatment (group B). HT was given alone, concurrent with systemic therapy (ST), that is, chemotherapy, biotherapy, or both, and with or without induction therapy (IT). Acute and late toxicities are reported using standard criteria; locoregional failure\/progression (LRF), distant metastases (DM), and second primary tumors (SPT) were documented, and event-free survival (EFS) and overall survival (OS) were calculated from the start of HT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Group A patients received HT alone in 22 cases and HT + ST in 20 cases; group B patients received HT alone in 17 cases and HT + ST in 88 cases. Severe (grade \u2265 3) acute mucosal toxicity and swallowing problems increased with more additional ST. After a median follow-up of 44 months, grade \u22652 late toxicity after HT + ST was approximately twice that of HT alone for skin, subcutis, pharynx, and larynx. Forty percent had grade \u22652 late xerostomia, and 29% had mucosal toxicity. At 3 years, LRF\/DM\/SPT occurred in 7%\/7%\/17% and 25%\/13%\/5% in groups A and B, respectively, leading to a 3-year EFS\/OS of 64%\/74% and 56%\/63% in groups A and B, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>The use of HT alone or in combination with ST is feasible and promising and has a low late fatality rate. However, late toxicity is nearly twice as high when ST is added to HT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0337","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T06:51:20Z","timestamp":1423723880000},"page":"279-290","source":"Crossref","is-referenced-by-count":7,"title":["Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience"],"prefix":"10.1093","volume":"20","author":[{"given":"Dirk","family":"Van Gestel","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, University Radiotherapy Antwerp UZA\/ZNA, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Van den Weyngaert","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Radiotherapy Antwerp UZA\/ZNA, Antwerp, Belgium;"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"De Kerf","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Radiotherapy Antwerp UZA\/ZNA, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bie","family":"De Ost","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Radiotherapy Antwerp UZA\/ZNA, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Vanderveken","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Van Laer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pol","family":"Specenier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmyne","family":"Geussens","sequence":"additional","affiliation":[{"name":"Iridium Kankernetwerk, Campus Nikolaas, Sint Niklaas, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Wouters","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium"},{"name":"Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Meulemans","sequence":"additional","affiliation":[{"name":"Data-Management Multidisciplinair Oncologisch Centrum Antwerpen, Antwerp University Hospital, Edegem, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin Jip","family":"Cheung","sequence":"additional","affiliation":[{"name":"Data-Management Multidisciplinair Oncologisch Centrum Antwerpen, Antwerp University Hospital, Edegem, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department and Centre for Molecular Imaging and Experimental Radiotherapy, St-Luc University Hospital, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan B.","family":"Vermorken","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,2,11]]},"reference":[{"key":"2021122309230081000_B1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to loco-regional treatment for head and neck squamous cell carcinoma: Three meta-analyses of update individual data","volume":"355","author":"Pignon","year":"2000","journal-title":"Lancet"},{"key":"2021122309230081000_B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0360-3016(96)00430-0","article-title":"Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial","volume":"36","author":"Bachaud","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122309230081000_B5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122309230081000_B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1634\/theoncologist.10-3-215","article-title":"Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?","volume":"10","author":"Bernier","year":"2005","journal-title":"The Oncologist"},{"key":"2021122309230081000_B7","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309230081000_B8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.12-5-555","article-title":"Intensity-modulated radiation therapy for head and neck carcinoma","volume":"12","author":"Gr\u00e9goire","year":"2007","journal-title":"The Oncologist"},{"key":"2021122309230081000_B9","first-page":"109","article-title":"Technological advances in external beam radiotherapy for head and neck cancer","volume":"9","author":"Van Gestel","year":"2013","journal-title":"Oncol Hematol Rev"},{"key":"2021122309230081000_B10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B11","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","article-title":"Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients","volume":"25","author":"Kam","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309230081000_B12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122309230081000_B13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.radonc.2012.07.001","article-title":"Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: A randomized controlled trial","volume":"104","author":"Gupta","year":"2012","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","article-title":"A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma","volume":"104","author":"Peng","year":"2012","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.28372","article-title":"Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis","volume":"120","author":"Beadle","year":"2014","journal-title":"Cancer"},{"key":"2021122309230081000_B16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122309230081000_B17","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122309230081000_B18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2010.03.028","article-title":"Adaptive dose painting by numbers for head-and-neck cancer","volume":"80","author":"Duprez","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.radonc.2003.10.012","article-title":"Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx","volume":"70","author":"Clark","year":"2004","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/CAD.0b013e328340fd2b","article-title":"New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions: Improved effectiveness and safety?: Impact on survival?","volume":"22","author":"Thariat","year":"2011","journal-title":"Anticancer Drugs"},{"key":"2021122309230081000_B21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1634\/theoncologist.2012-0424","article-title":"The potential of helical tomotherapy in the treatment of head and neck cancer","volume":"18","author":"Van Gestel","year":"2013","journal-title":"The Oncologist"},{"key":"2021122309230081000_B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"Green","year":"2002","edition":"6th ed."},{"key":"2021122309230081000_B23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1148\/radiol.2331030660","article-title":"Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen","volume":"233","author":"Daisne","year":"2004","journal-title":"Radiology"},{"key":"2021122309230081000_B24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2967\/jnumed.110.075689","article-title":"Molecular imaging in radiotherapy planning for head and neck tumors","volume":"52","author":"Gr\u00e9goire","year":"2011","journal-title":"J Nucl Med"},{"key":"2021122309230081000_B25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2003.09.011","article-title":"CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines","volume":"69","author":"Gr\u00e9goire","year":"2003","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2006.03.009","article-title":"Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck","volume":"79","author":"Gr\u00e9goire","year":"2006","journal-title":"Radiother Oncol"},{"issue":"suppl 1","key":"2021122309230081000_B27","doi-asserted-by":"crossref","first-page":"S171a","DOI":"10.1016\/S0167-8140(12)73038-4","article-title":"Evaluation of megavolt CT imaging protocols in the treatment of head and neck cancer with helical tomotherapy","volume":"92","author":"De Ost","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B28","volume-title":"ICRU Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50)","author":"International Commission on Radiation Units and Measurements","year":"2000"},{"key":"2021122309230081000_B29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.radonc.2013.06.044","article-title":"Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT): Dosimetrical analysis and effect on acute toxicity","volume":"109","author":"Nuyts","year":"2013","journal-title":"Radiother Oncol"},{"key":"2021122309230081000_B30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1748-717X-8-37","article-title":"RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison","volume":"8","author":"Van Gestel","year":"2013","journal-title":"Radiat Oncol"},{"key":"2021122309230081000_B31","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1118\/1.3005481","article-title":"A new formalism for reference dosimetry of small and nonstandard fields","volume":"35","author":"Alfonso","year":"2008","journal-title":"Med Phys"},{"key":"2021122309230081000_B32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1118\/1.1855015","article-title":"Dose calibration of nonconventional treatment systems applied to helical tomotherapy","volume":"32","author":"Jeraj","year":"2005","journal-title":"Med Phys"},{"key":"2021122309230081000_B33","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1118\/1.1897084","article-title":"A Monte Carlo derived TG-51 equivalent calibration for helical tomotherapy","volume":"32","author":"Thomas","year":"2005","journal-title":"Med Phys"},{"key":"2021122309230081000_B34","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1118\/1.3651496","article-title":"Reference dosimetry for helical tomotherapy: Practical implementation and a multicenter validation","volume":"38","author":"De Ost","year":"2011","journal-title":"Med Phys"},{"key":"2021122309230081000_B35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B36","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"2021122309230081000_B37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021122309230081000_B38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/1471-2407-13-610","article-title":"Results of concurrent radio-chemotherapy for the treatment of head and neck squamous cell carcinoma in everyday clinical practice with special reference to early mortality","volume":"13","author":"Schlumpf","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122309230081000_B39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1259\/bjr\/67058055","article-title":"Intensity-modulated radiotherapy in patients with head and neck cancer: A European single-centre experience","volume":"84","author":"Van Gestel","year":"2011","journal-title":"Br J Radiol"},{"key":"2021122309230081000_B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3857\/roj.2013.31.1.1","article-title":"Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer","volume":"31","author":"Kong","year":"2013","journal-title":"Radiat Oncol J"},{"key":"2021122309230081000_B41","doi-asserted-by":"crossref","first-page":"401261","DOI":"10.1155\/2013\/401261","article-title":"The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: A systematic review with dosimetric and clinical parameters","volume":"2013","author":"Kouloulias","year":"2013","journal-title":"Biomed Res Int"},{"key":"2021122309230081000_B42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.7785\/tcrt.2012.500192","article-title":"Comparison of IMRT techniques in the radiotherapeutic management of head and neck cancer: Is tomotherapy \u201cbetter\u201d than step-and-shoot IMRT?","volume":"10","author":"Chen","year":"2011","journal-title":"Technol Cancer Res Treat"},{"key":"2021122309230081000_B43","volume-title":"Oral cavity cancer: Diagnosis, treatment and follow-up: good clinical Practice (GCP). KCE Reports 227Cs. D\/2014\/10.273\/57","author":"Gr\u00e9goire","year":"2014"},{"key":"2021122309230081000_B44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","article-title":"Loss of local control with prolongation in radiotherapy","volume":"23","author":"Fowler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0360-3016(97)00466-5","article-title":"Applying radiobiological principles to combined modality treatment of head and neck cancer: The time factor","volume":"39","author":"Peters","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B46","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/j.ijrobp.2010.12.005","article-title":"Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: A subset analysis of TAX 324","volume":"81","author":"Sher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309230081000_B47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00066-010-2130-5","article-title":"Pattern of failure after helical tomotherapy in head and neck cancer","volume":"186","author":"Farrag","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"2021122309230081000_B48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdr006","article-title":"Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial","volume":"22","author":"Posner","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122309230081000_B49","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2010.29.2904","article-title":"Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309230081000_B50","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/annonc\/mdp573","article-title":"Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study","volume":"21","author":"Paccagnella","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2021122309230081000_B51","doi-asserted-by":"crossref","first-page":"5500a","DOI":"10.1200\/jco.2012.30.15_suppl.5500","article-title":"DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2\/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"30","author":"Cohen","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309230081000_B52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122309230081000_B53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2021122309230081000_B54","doi-asserted-by":"crossref","first-page":"6004a","DOI":"10.1200\/jco.2014.32.15_suppl.6004","article-title":"Concomitant chemoradiation (CRT) or cetuximab\/RT (CET\/RT) versus induction docetaxel\/cisplatin\/5-fluorouracil (TPF) followed by CRT or CET\/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN): A randomized phase III factorial study","volume":"32","author":"Ghi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309230081000_B55","doi-asserted-by":"crossref","first-page":"6014a","DOI":"10.1200\/jco.2014.32.15_suppl.6014","article-title":"Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: A meta-analysis of published trials","volume":"32","author":"Barni","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/3\/279\/41868199\/oncolo_20_3_279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/3\/279\/41868199\/oncolo_20_3_279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:22:25Z","timestamp":1640312545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/3\/279\/6399897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,11]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,11]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0337","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,3,1]]},"published":{"date-parts":[[2015,2,11]]}}}